（原标题：兆科眼科-B(06622)拟与东生华制药于台湾地区共同推进BRIMOCHOL?PF的临床导论及未来 商业化） 于2025年6月，兆科的伙伴兼BRIMOCHOL PF的开发商Tenpoint Therapeutics, Ltd.宣布，美国FDA已受理 该药品的新药上市申请。FDA已就BRIMOCHOLPF制定处方药使用者付费法案(Prescription Drug User Fee Act)(PDUFA)，审核截止日期为2026年1月28日。 智通财经APP讯，兆科眼科-B(06622)公布，公司与以台湾为基地的东生华制药股份有限公司订立策略性 伙伴关系，于台湾地区共同推进BRIMOCHOL PF的临床导论及未来商业化。东生华制药精于慢性病及 精准医疗，提供安全而易于获取的照护解决方案。根据协议条款，兆科授予东生华制药以独家分销商身 份于台湾地区注册、进口、推广、分销、营销及销售BRIMOCHOL PF的权利。 ...

于2025年6月，兆科的伙伴兼BRIMOCHOL PF的开发商Tenpoint Therapeutics,Ltd.宣布，美国FDA已受理 该药品的新药上市申请。FDA已就BRIMOCHOL PF制定处方药使用者付费法案(Prescription Drug User Fee Act)(PDUFA)，审核截止日期为2026年1月28日。 兆科眼科-B(06622)公布，公司与以台湾为基地的东生华制药股份有限公司订立策略性伙伴关系，于台 湾地区共同推进BRIMOCHOL PF的临床导论及未来商业化。东生华制药精于慢性病及精准医疗，提供 安全而易于获取的照护解决方案。根据协议条款，兆科授予东生华制药以独家分销商身份于台湾地区注 册、进口、推广、分销、营销及销售BRIMOCHOL PF的权利。 ...

Core Viewpoint - Zhaoke Ophthalmology-B (06622) experienced a nearly 10% increase in stock price, reaching HKD 3.7 with a trading volume of HKD 6.55 million following the announcement of a distribution and supply agreement in Indonesia for its innovative drug BRIMOCHOL PF, aimed at treating presbyopia [1] Company Summary - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron Par Pharmaceuticals, a leading pharmaceutical company in Indonesia [1] - The agreement grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL PF in Indonesia [1] - Zhaoke Ophthalmology will receive an upfront payment and may earn additional milestone payments based on certain achievements [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant increase in stock price, rising over 7% following the announcement of a distribution and supply agreement with PT Ferron Pharmaceuticals for its innovative drug BRIMOCHOL PF, aimed at treating presbyopia in the Indonesian market [1] Group 1: Company Developments - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron Pharmaceuticals for BRIMOCHOL PF, granting PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia [1] - The agreement includes an upfront payment to Zhaoke Ophthalmology, along with potential milestone payments based on certain achievements [1] Group 2: Product and Regulatory Updates - BRIMOCHOL PF is an innovative drug developed by Tenpoint Therapeutics, which has had its new drug application accepted by the U.S. FDA, with a PDUFA date set for January 28, 2026 [1]

Company News - BeiGene reported total revenue of approximately $3.845 billion for the first nine months, a year-on-year increase of 43%. Adjusted net profit was approximately $693 million, marking a return to profitability. In Q3, revenue reached $1.412 billion, up 41% year-on-year, with adjusted net profit of approximately $304 million, a 489% increase year-on-year. The growth is primarily attributed to the sales increase of BeiYueZe® in the US and Europe, with the US remaining the largest market for the company. The full-year revenue guidance is set at $5.1 billion to $5.3 billion, reflecting strong growth expectations from BeiYueZe® in the US and continued expansion in Europe and other key global markets [2] - Yidu International Holdings announced an earnings upgrade, expecting a profit attributable to shareholders of approximately HKD 1.2 billion for the first half, representing an increase year-on-year [3] - Hua Hong Semiconductor reported sales revenue of $635 million for Q3 2025, a year-on-year increase of 20.7%. However, net profit decreased by 42.6% to $25.725 million [4] - Autohome's net profit attributable to the parent company for Q3 was approximately RMB 436.6 million, with online marketing and other business revenues increasing by 32.1% year-on-year [5] - Xinyi International reported a cumulative net operating income of approximately HKD 13.981 billion for the first ten months, a year-on-year decrease of about 5.3%, with October revenue at HKD 1.457 billion [6] - Dongfeng Motor Group's cumulative vehicle sales for the first ten months reached 1.501 million units, a year-on-year decline of approximately 1.6%. However, sales of new energy vehicles increased by approximately 37.1% to 421,400 units [7] - China Overseas Land & Investment reported a cumulative contracted property sales amount of approximately RMB 189.165 billion for the first ten months, a year-on-year decrease of 21.3% [8] - Poly Property Group reported a cumulative contracted sales amount of RMB 43.8 billion for the first ten months, a year-on-year decrease of 10.43% [9] - Gemdale reported a cumulative contracted sales amount of approximately RMB 9.125 billion for the first ten months, a year-on-year decrease of 43.93% [10] - Sunac China reported a cumulative contract sales amount of approximately RMB 32.77 billion for the first ten months, a year-on-year decline of 25.1% [11] - Guoyin Financial Leasing plans to purchase 1,198 units of domestic information technology computing equipment for a total consideration of RMB 1.04 billion [12] - Youjia Innovation recently received project designation notifications from a globally renowned automotive group's joint venture and luxury brand, with a total order amount of approximately RMB 320 million [13] - Swire Properties reported a rental rate of 96% for Taikoo Place in Q3, with a rental reduction of 13%. Other Swire properties had an occupancy rate of 90%, with a rental reduction of 15% [14] - Zhongshen Construction Industry plans to acquire 100% equity of Huajian Development Co., Ltd. for approximately HKD 213.6 million [15] - Hard Egg Innovation signed a memorandum of understanding with Huixin Investment to jointly develop an AIoT innovation enterprise incubation platform [16] - Damai Entertainment expects mid-term net profit to increase to no less than RMB 500 million, compared to RMB 337 million last year [17] - Cafe de Coral Group issued a profit warning, expecting mid-term profit attributable to shareholders to decline by 65% to 70% [18] - Qingci Games signed a game licensing transfer agreement with Disney, obtaining authorization to develop and publish the game "Disney: Book of Legends," expected to launch in 2026 across various regions [19] - Now Medical Technology's subsidiary signed a strategic cooperation framework agreement with Medtronic Changzhou to promote clinical applications of real-time navigation tracking endoscopic technology in China [19] - Zhaoke Ophthalmology-B signed a distribution agreement with PT FERRON for the commercialization of BRIMOCHOL PF in Indonesia, receiving an upfront payment and potential milestone payments [19] - Shoujia Technology signed a strategic framework cooperation agreement with Stardust Intelligence, covering the development of humanoid robot tendon and related fields [20] Buyback Dynamics - Helen's decided to exercise its share buyback authorization, planning to repurchase up to 127 million shares [21] - China Feihe repurchased 6.806 million shares for a total of approximately HKD 29.4298 million, with a buyback price of HKD 4.29 to HKD 4.35 [22] - Kintor Pharmaceutical repurchased 1.734 million shares for a total of approximately HKD 26.3078 million, with a buyback price of HKD 14.35 to HKD 15.8 [23] - COSCO Shipping Holdings repurchased 1.53 million shares for a total of approximately HKD 20.9869 million, with a buyback price of HKD 13.57 to HKD 13.84 [24] - Sinopec repurchased 2.398 million H-shares for a total of approximately HKD 10.1066 million, with a buyback price of HKD 4.20 to HKD 4.23 [25]

Group 1 - Company Zhaoke Ophthalmology-B (06622) has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL PF in Indonesia [1] - The agreement grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL PF in Indonesia, with the company receiving an upfront payment and potential milestone payments based on specific achievements [1] - BRIMOCHOL PF is an experimental preservative-free eye drop designed to correct near vision loss due to aging, with a new drug application accepted by the FDA, and a review deadline set for January 28, 2026 [1][2] Group 2 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is recognized as one of the top 15 largest pharmaceutical companies in Indonesia [3] - The company has received recognition from regulatory bodies such as the UK's Medicines and Healthcare products Regulatory Agency and Portugal's National Authority of Medicines and Health Products, enhancing its credibility [3] - PT Ferron is known for its diverse product portfolio, advanced production capabilities, and strong strategic partnerships, which contribute to its growing market influence and operational excellence [3]

Group 1 - The company has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL PF in Indonesia, which is an innovative drug licensed by Tenpoint Therapeutics for the treatment of presbyopia [1] - Under the agreement, the company grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL PF in Indonesia, and will receive an upfront payment along with potential milestone payments based on specific achievements [1] - The developer of BRIMOCHOL PF, Tenpoint, announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026 [1] Group 2 - BRIMOCHOL PF is a preservative-free, experimental eye drop intended for correcting near vision loss due to aging, and is part of a multi-center, randomized, double-blind study involving 629 participants across 47 trial centers in the U.S. [2] - The study compares the safety and efficacy of BRIMOCHOL PF against other formulations, including a single-agent therapy and a carrier eye drop [2] Group 3 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is recognized as one of the top 15 largest pharmaceutical companies in Indonesia according to IQVIA's data [3] - The company has received recognition from regulatory bodies such as the UK's Medicines and Healthcare products Regulatory Agency and Portugal's National Authority of Medicines and Health Products, enhancing its credibility [3] - PT Ferron is strengthening its market influence and operational capabilities through a diversified product portfolio, advanced production capabilities, and strong strategic partnerships [3]

Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the six months ending June 30, 2025, primarily due to changes in sales strategy and increased R&D expenses [1] Financial Performance - Revenue for the period was 15.803 million, representing a year-on-year decrease of 68.25% [1] - The net loss amounted to 117 million, which is an increase of 53.85% compared to the previous period [1] Reasons for Financial Changes - The increase in net loss is attributed to the absence of one-time licensing income recognized in the previous period under a product licensing agreement [1] - Increased R&D expenses were driven by the initiation of Phase I and II clinical trials for BRIMOCHOL PF and CARBACHOL PF, as well as a new Phase III clinical trial for cyclosporine eye gel [1] - The decrease in revenue is linked to the company's shift in sales strategy, focusing on expanding the distribution network for ophthalmic drugs and restructuring the sales team to concentrate on key sales regions [1]